Median overall survival was numerically higher with datopotamab deruxtecan but did not reach statistical significance in either the overall population or the prespecified non-squamous subgroup, illustrating the importance of histologic context in TROP2-targeted therapy [ 90 ].
← all excerpts
Antibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression: A Mechanistic, Translational, and Clinical Review
1
—
—